新検索ページはこちら
ログイン
お問い合わせ
有効性評価に基づく前立腺がん検診ガイドライン
書誌情報
引用文献
文献
| 1） | 国立がんセンターがん対策情報センター http://ganjoho.ncc.go.jp/professional/statistics/index.html（2007.7.20.アクセス） |
| 2） | 統計で見る大阪府のがん―がん死亡の激減を目指して―（大阪府立成人病センター調査部）2006. |
| 3） | Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859-64. |
| 4） | Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five contonuens. Vol VII.Lyon:IARC Sci Publ,1997. |
| 5） | Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982;29(6):611-6. |
| 6） | Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. 2005;97(23):1768-77. |
| 7） | 平成12年度厚生労働省老人保健事業推進費等補助金 がん検診の適正化に関する調査研究事業 新たながん検診手法の有効性評価報告書（主任研究者 久道茂）．2001．公衆衛生協会． |
| 8） | 厚生労働省老人保健課・がん検診検討会（平成19年6月26日）参考資料5.市町村におけるがん検診の実施状況等及び事業費に関する調査結果．2007． |
| 9） | 平成16年度厚生労働省がん研究助成金 がん検診の適切な方法とその評価法の確立に関する研究班（主任研究者 祖父江友孝）有効性評価に基づくがん検診ガイドライン作成手順．2005． |
| 10） | National Institute for Health and Clinical Excellence. Methods for development of NICE public health guidance. 2006. |
| 11） | Briss PA, Zaza S, Pappaioanou M, Fielding J, Wright-De Agüero L, Truman BI, Hopkins DP, Mullen PD, Thompson RS, Woolf SH, Carande-Kulis VG, Anderson L, Hinman AR, McQueen DV, Teutsch SM, Harris JR. Developing an evidence-based Guide to Community Preventive Services--methods. The Task Force on Community Preventive Services. Am J Prev Med. 2000;18(1 Suppl):35-43. |
| 12） | Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW Jr, Zaza S; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. |
| 13） | Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21-35. |
| 14） | Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ. 2003;169(3):207-8. |
| 15） | Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developer's handbook. 2004. |
| 16） | 平成16年度厚生労働省がん研究助成金 がん検診の適切な方法とその評価法の確立に関する研究班（主任研究者 祖父江友孝）有効性評価に基づく大腸がん検診ガイドライン．2005． |
| 17） | Mulrow CD. Rationale for systematic reviews. BMJ. 1994;309(6954):597-9. |
| 18） | Woolf SH. Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. Arch Intern Med. 1992;152(5):946-52. |
| 19） | National Institute for Health and Clinical Excellence. Guideline development methods: Information for National Collaborating Centers and guideline developers. 2004. |
| 20） | ERSPC（European Randomized Study of Screening for Prostate Cancer）. http://www.erspc.org/（2006.10.1アクセス） |
| 21） | PLCO（Prostate, Lung, Colorectal and Ovarian）Publications. https://www.parplco.org/DesktopDefault.aspx?tabindex=1&tabid=144&tablevel=1&portalId=0（2006.10.1アクセス） |
| 22） | Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(11):917-29. |
| 23） | Gilliland F, Becker TM, Smith A, Key CR, Samet JM. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev. 1994;3(2):105-11. |
| 24） | Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet. 1991;337(8756):1526-9. |
| 25） | Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen. 1998;5(2):99-103. |
| 26） | Weinmann S, Richert-Boe K, Glass AG, Weiss NS. Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control. 2004;15(2):133-8. |
| 27） | Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology. 1998;52(2):173-9. |
| 28） | Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16(2):95-101. |
| 29） | 加野象二郎．前立腺特異抗原（PSA）の標準化に関する活動報告．日本臨床検査標準協議会会誌. 2006;21(1):9-47. |
| 30） | Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, Chevrette E, Levesque J. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59(3):311-8. |
| 31） | Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Lévesque J, Belanger A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38(2):83-91. |
| 32） | Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46(6):717-23; discussion 724. |
| 33） | Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol. 2007;51(3):659-64. Epub 2006 Jul 28. |
| 34） | Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control. 2007;18(3):279-85. Epub 2007 Jan 6. |
| 35） | Ciatto S, Gervasi G, Gorini G, Lombardi C, Zappa M, Crocetti E. Prostate cancer specific mortality in the Florence screening pilot study cohort 1992-1993. Eur J Cancer. 2006;42(12):1858-62. Epub 2006 Jul 7. |
| 36） | 中川修一，中村晃和，渡辺泱．前立腺がん検診の有効性と適切な受診間隔を検討するためのケース・コントロール研究．日本泌尿器科学会雑誌．1998;89(11):894-8. |
| 37） | Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med. 2006;166(1):38-43. |
| 38） | Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol. 2005;174(2):495-9; discussion 499. |
| 39） | Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325(7367):740. |
| 40） | Perron L, Moore L, Bairati I, Bernard PM, Meyer F. PSA screening and prostate cancer mortality. CMAJ. 2002;166(5):586-91. |
| 41） | Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ. 2003;168(1):31-5. |
| 42） | La Rosa F, Stracci F, Minelli L, Mastrandrea V. Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects. Urology. 2003;62(6):1040-4. |
| 43） | Threlfall TJ, English DR, Rouse IL. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust. 1998;169(1):21-4. |
| 44） | Skarsgard D, Tonita J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control. 2000;11(1):79-88. |
| 45） | Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU Int. 2000;85(9):1058-62. |
| 46） | Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995. Eur J Cancer. 1998 Apr;34(5):705-9. |
| 47） | Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int. 2000;85(4):463-72; discussion 472-3. |
| 48） | Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 1999;161(2):529-33. |
| 49） | Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004;160(11):1059-69. |
| 50） | Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev. 2005;14(3):590-5. |
| 51） | Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004;15(3):237-41. |
| 52） | Oberaigner W, Horninger W, Klocker H, Schönitzer D, Stühlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164(4):376-84. Epub 2006 Jul 7. |
| 53） | Vutuc C, Schernhammer ES, Haidinger G, Waldhör T. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr. 2005;117(13-14):457-61. |
| 54） | Melia J, Dearnaley D, Moss S, Johns L, Coulson P, Moynihan C, Sweetman J, Parkinson MC, Eeles R, Watson M. The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk. Br J Cancer. 2006;94(4):499-506. |
| 55） | Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol. 2002;168(5):1980-3; discussion 1983-4. |
| 56） | Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147(3 Pt 2):846-51; discussion 851-2. |
| 57） | Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344(8937):1594-8. |
| 58） | Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol. 1995;154(3):1085-9. |
| 59） | Jacobsen SJ, Bergstralh EJ, Guess HA, Katusic SK, Klee GG, Oesterling JE, Lieber MM. Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med. 1996;156(21):2462-8. |
| 60） | Ito K, Yamamoto T, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology. 2000;56(2):278-82. |
| 61） | Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol. 2001;166(6):2189-91; discussion 2191-2. |
| 62） | van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst. 2003;95(19):1462-6. |
| 63） | Auvinen A, Määttänen L, Finne P, Stenman UH, Aro J, Juusela H, Rannikko S, Tammela TL, Hakama M. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. Int J Cancer. 2004;111(6):940-3. |
| 64） | McLernon DJ, Donnan PT, Gray M, Weller D, Sullivan F. Receiver operating characteristics of the prostate specific antigen test in an unselected population. J Med Screen. 2006;13(2):102-7. |
| 65） | Postma R, van Leenders AG, Roobol MJ, Schröder FH, van der Kwast TH. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol. 2006;50(1):70-5. |
| 66） | Kubota Y, Ito K, Imai K, Yamanaka H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate. 2002;50(4):262-9. |
| 67） | McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ. 1998;159(11):1368-72. |
| 68） | Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, Lodding P, Tibblin G. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int. 2000;85(9):1078-84. |
| 69） | Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-90. |
| 70） | Auvin A, Määttänen L, Stenman UH, Tammela T, Rannikko S, Aro J, Juusela H, Hakama M. Lead-time in prostate cancer screening (Finland). Cancer Causes Control. 2002;13(3):279-85. |
| 71） | Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-78. |
| 72） | Törnblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, Hugosson J. Lead time associated with screening for prostate cancer. Int J Cancer. 2004;108(1):122-9. |
| 73） | Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997;49(6):875-80. |
| 74） | Mkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology. 2002;60(5):846-50. |
| 75） | Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G. Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol. 2005;12 Suppl 1:7-13; discussion 92-3. |
| 76） | Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM, Whalen E, Kowalsky SF. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998;52(4):552-8. |
| 77） | Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990. J Urol. 2002;167(2 Pt 2):966-73; discussion 973-5. |
| 78） | Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol. 1998;160(6 Pt 1):2115-20. |
| 79） | Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C, Marberger M. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001;166(3):856-60. |
| 80） | Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002;60(5):826-30. |
| 81） | Crawford ED, Haynes AL Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol. 1982;127(3):449-51. |
| 82） | Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000;85(6):682-5. |
| 83） | Norberg M, Holmberg L, Häggman M, Magnusson A. Determinants of complications after multiple transrectal core biopsies of the prostate. Eur Radiol. 1996;6(4):457-61. |
| 84） | 熊谷章，小川大輔，小山敏樹，竹内一郎，大山格．経直腸的前立腺生検後にフルニエ壊疽を発症した管理不良な糖尿病患者の1例．日本泌尿器科学会雑誌．2002;93(5):648-51. |
| 85） | 長谷川太郎，下村達也，山田裕紀，伊藤博之，加藤伸樹，長谷川倫男，浅野晃司，清田浩，池本庸，小野寺昭一，大石幸彦．経直腸的前立腺針生検による敗血症性ショックの1死亡例．感染症学雑誌．2002;76(10):893-7. |
| 86） | Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354-60. |
| 87） | Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer. 2002;95(11):2397-407. |
| 88） | Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269(20):2633-6. |
| 89） | Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, Holmberg L; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790-6. |
| 90） | Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358-67. |
| 91） | Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92(19):1582-92. |
| 92） | Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19(6):1619-28. |
| 93） | Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16(1):275-83. |
| 94） | Arai Y, Egawa S, Tobisu K, Sagiyama K, Sumiyoshi Y, Hashine K, Kawakita M, Matsuda T, Matsumoto K, Fujimoto H, Okada T, Kakehi Y, Terachi T, Ogawa O. Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan. BJU Int. 2000;85(3):287-94. |
| 95） | Hisasue S, Takahashi A, Kato R, Shimizu T, Masumori N, Itoh N, Tsukamoto T. Early and late complications of radical retropubic prostatectomy: experience in a single institution. Jpn J Clin Oncol. 2004;34(5):274-9. |
| 96） | Morrison AS. Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol. 1991;20(3):642-50. |
| 97） | Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. |
| 98） | Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-8. |
| 99） | Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322(12):802-9. |
| 100） | Becker N. Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol. 2003;129(12):691-702. |
| 101） | Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548-52. |
| 102） | Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 1998;9(5):519-27. |
| 103） | Mettlin C. Impact of screening on prostate cancer rates and trends. Microsc Res Tech. 2000;51(5):415-8. |
| 104） | Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001;23(1):181-6. |
| 105） | Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91(12):1017-24. |
| 106） | Stone NN, DeAntoni EP, Crawford ED. Screening for prostate cancer by digital rectal examination and prostate-specific antigen: Results of Prostate Cancer Awareness week, 1989-1992. Urology Symposium. 1994;44:18-25. |
| 107） | Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91(12):1025-32. |
| 108） | Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119(9):914-23. |
| 109） | Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328(17):1237-43. |
| 110） | Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66. |
| 111） | 財団法人前立腺研究財団．前立腺がん検診市町村実施状況（2006年10月調査）．2007． |
| 112） | 平成17年度厚生労働省がん研究助成金 がん検診の適切な方法とその評価法の確立に関する研究班（主任研究者 祖父江友孝）有効性評価に基づく胃がん検診ガイドライン．2006． |
| 113） | 平成18年度厚生労働省がん研究助成金 がん検診の適切な方法とその評価法の確立に関する研究班（主任研究者 祖父江友孝）有効性評価に基づく肺がん検診ガイドライン．2006． |
| 114） | Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995. Bethesda.Md: SEER program, National Cancer Institute; 1999. National Institute of Health publication No.99-4543. |
| 115） | Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977-84. |
| 116） | Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713-9. |
| 117） | Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095-101. |
| 118） | Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006 Nov 15;296(19):2336-42. |
| 119） | Miles A, Cockburn J, Smith RA, Wardle J. A perspective from countries using organized screening programs. Cancer. 2004;101(5 Suppl):1201-13. |
| 120） | Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC. Evaluation of screening programmes for gynaecological cancer. Br J Cancer. 1985;52(4):669-73. |
| 121） | Holland W. Screening for disease: considerations for policy. Eur Observer. 2006;8:1-8. |
| 122） | Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin. 2007;57(2):90-104. |
| 123） | Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park). 2000;14(2):267-72, 277-8, 280 passim. |
| 124） | 日本泌尿器科学会編．前立腺癌診療ガイドライン2006年版．金原出版．東京．2006． |
| 125） | National Cancer Institute. Cancer Information Summaries: Screening/Detection (Testing for Cancer) Prostate cancer screening: Summary of evidence. http://www.cancer.gov/cancertopics/pdq/screening/prostate/healthprofessional（2007.7.2アクセス） |
| 126） | Feightner J.W. Screening for prostate cancer. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada, 1994; 812-823. |
| 127） | American Academy of Family Physicians. AAFP Summary of Recommendations for Clinical Preventive Services. 2007. |
| 128） | VA National Center for Health Promotion and Disease Prevention. Proposal for new Clinical Practice Guideline for Screening Men for Prostate Cancer. 2004. |
| 129） | National Comprehensive Cancer Network. And American Cancer Society. Prostate cancer: Treatment guideline for patients (Version V). 2005. |
| 130） | Davidson P, Gabby J. Should mass screening for prostate cancer be introduced at the national level? Health Evidence Network (WHO Europe) 2004. |
| 131） | Heindenrich H, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, Scmid HP, Zattoni F. Guideline on prostate cancer. European Association of Urology. 2007. |
| 132） | Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localized prostate cancer. Health Technology Assessment 1997; Vol 1: number 2. The NHS Health Technology Assessment Programme. |
| 133） | NHS National Cancer Screening Programmes. Prostate Cancer Risk Management http://www.cancerscreening.nhs.uk/prostate/index.html（2007.7.28アクセス） |
| 134） | European Code Against Cancer third edition. http://www.cancercode.org/add_items.htm（2007.7.28アクセス） |
| 135） | Schersten T, Baile A; Asua J, Jonsson E. Prostate Cancer Screening: Evidence Synthesis and Update Statements of Findings. INAHTA: International Network of Agencies for Health Technology Assessment.1999. http://inahta.episerverhotell.net/Publications/Joint-Synthesis/2314/（2007.7.28アクセス） |
| 136） | National Health Committee. Prostate cancer screening in New Zeeland: Report to the Minister of Health. 2004. |
| 137） | Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E; U.S. Preventive Services Task Force. Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med. 2007;147(2):117-22. |
| 138） | Barton MB, Miller T, Wolff T, Petitti D, LeFevre M, Sawaya G, Yawn B, Guirguis-Blake J, Calonge N, Harris R; U.S. Preventive Services Task Force. Ann Intern Med. 2007;147(2):123-7. |
| 139） | U.S. Preventive Services Task Force. Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;147(2):128-34. |
| 140） | Sheridan SL, Harris RP, Woolf SH; Shared Decision-Making Workgroup of the U.S. Preventive Services Task Force. Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004;26(1):56-66. |
| 141） | Briss P, Rimer B, Reilley B, Coates RC, Lee NC, Mullen P, Corso P, Hutchinson AB, Hiatt R, Kerner J, George P, White C, Gandhi N, Saraiya M, Breslow R, Isham G, Teutsch SM, Hinman AR, Lawrence R; Task Force on Community Preventive Services. Promoting informed decisions about cancer screening in communities and healthcare systems. Am J Prev Med. 2004;26(1):67-80. |
| 142） | Hamashima C, Saito H, Sobue T. Awareness of and adherence to cancer screening guidelines among health professionals in Japan. Cancer Sci. 2007;98(8):1241-7. |
| 143） | 日本泌尿器科学会（医療関係者の皆様へ）厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班「前立腺がん検診の有効性評価に関する検証」に対する泌尿器科学会の見解（http://www.urol.or.jp/kankeisya/info/prostate_exam.html）（2007.9.30アクセス） |
| 144） | Schröder FH, Habbema DF, Roobol MJ, Bangma CH. Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction. Eur Urol. 2007;51(3):588-90. |
| 145） | Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med. 2004;350(19):2010-1. |
